13D Filing: Levin Capital Strategies and Fluidigm Corp (FLDM)

Page 12 of 21

Page 12 of 21 – SEC Filing

(d)
During the last five years, no Reporting Person, nor any person listed on Appendix A, has been convicted in a criminal proceeding
(excluding traffic violations or similar misdemeanors).

(e)
During the last five years, no Reporting Person, nor any person listed on Appendix A, has been a party to a civil proceeding
of a judicial or administrative body of competent jurisdiction that resulted in such Reporting Person being subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities
laws or finding any violation with respect to such laws.

(f)
Except as set forth on Appendix A, Levin and each person listed on Appendix A is a citizen of the United States of America.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

The Shares purchased by LCS were purchased with
general investment funds in open market purchases, except as otherwise noted. The aggregate purchase price of the 11,395,014 Shares
owned directly by LCS is approximately $66,425,633, including brokerage commissions.

The Shares purchased by Trilogy were purchased
with general investment funds in open market purchases, except as otherwise noted. The aggregate purchase price of the 82,884 Shares
owned directly by Trilogy is approximately $504,310, including brokerage commissions.

The Shares purchased by Levcap were purchased
with general investment funds in open market purchases, except as otherwise noted. The aggregate purchase price of the 56,820 Shares
owned directly by Levcap is approximately $280,825, including brokerage commissions.

The Shares purchased by Safinia were purchased
with general investment funds in open market purchases, except as otherwise noted. The aggregate purchase price of the 19,818 Shares
owned directly by Safinia is approximately $107,616, including brokerage commissions.

To the best of the Reporting Persons’ knowledge,
none of the persons listed on Appendix A beneficially owns any securities of the Issuer.

ITEM 4. PURPOSE OF TRANSACTION.

The Reporting Persons purchased the Shares based
on the Reporting Persons’ belief that the Shares, when purchased, were undervalued and represented an attractive investment
opportunity. The Reporting Persons remain passive investors in the Issuer and are filing the Schedule 13D as a result of acquiring
over 20% of the outstanding Shares of the Issuer. The Reporting Persons have not acquired the Shares with a purpose or effect of
changing or influencing control of the Issuer and no Reporting Person has any present plan or proposal which would relate to or
result in any of the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D. The Reporting Persons may acquire
or dispose of Shares in the future.

12

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 12 of 21